Assignee
ANAPTYSBIO INC
US·18 granted patents·22 pending applications·86 citations·filing 2010–2025
Top patents by PatentIndex Score
40 records- 0196US10738117B2Antibodies directed against programmed death-1 (PD-1)ANAPTYSBIO INC·Filed 2017·Granted Aug 11, 2020·10 cites·9 claims
- 0295US9815897B2Antibodies directed against programmed death-1 (PD-1)ANAPTYSBIO INC·Filed 2014·Granted Nov 14, 2017·24 cites·44 claims
- 0393US10526410B2Antibodies directed against interleukin 36 receptor (IL-36R)ANAPTYSBIO INC·Filed 2016·Granted Jan 7, 2020·7 cites·28 claims
- 0491US10508149B2Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)ANAPTYSBIO INC·Filed 2016·Granted Dec 17, 2019·7 cites·25 claims
- 0590US11753472B2Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)ANAPTYSBIO INC·Filed 2021·Granted Sep 12, 2023·2 cites·19 claims
- 0690US9133269B2Humanized antibodies directed against complement protein C5ANAPTYSBIO INC·Filed 2013·Granted Sep 15, 2015·20 cites·34 claims
- 0788US11130814B2Method of treating pustular psoriasis with antibodies directed against interleukin 36 receptor (IL-36R)ANAPTYSBIO INC·Filed 2019·Granted Sep 28, 2021·2 cites·27 claims
- 0888US10059764B2Antibodies directed against interleukin-33 (IL-33) and methods of making and usingANAPTYSBIO INC·Filed 2015·Granted Aug 28, 2018·6 cites·28 claims
- 0987US11155624B2Antibodies directed against programmed death-1 (PD-1)ANAPTYSBIO INC·Filed 2017·Granted Oct 26, 2021·4 cites·14 claims
- 1085US11352427B2Antibodies directed against T Cell immunoglobulin and mucin protein 3 (TIM-3)ANAPTYSBIO INC·Filed 2019·Granted Jun 7, 2022·2 cites·10 claims
- 1184US2024294631A1Antibodies directed against interleukin-33 (il-33)ANAPTYSBIO INC·Filed 2024·Application pending·0 cites
- 1282US2026022181A1Antibodies directed against interleukin 36 receptor (il-36r)ANAPTYSBIO INC·Filed 2025·Application pending·0 cites
- 1382US2023331843A1Antibodies Directed Against Programmed Death-1(PD-1)ANAPTYSBIO INC·Filed 2023·Application pending·0 cites
- 1481US10836820B2Method of treating inflammatory disorder with antibodies directed against interleukin-33 (IL-33)ANAPTYSBIO INC·Filed 2018·Granted Nov 17, 2020·1 cites·8 claims
- 1576US2023416368A1Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3)ANAPTYSBIO INC·Filed 2023·Application pending·0 cites
- 1674US11999783B2Method of treating autoimmune disease with antibodies against IL-33ANAPTYSBIO INC·Filed 2020·Granted Jun 4, 2024·0 cites·12 claims
- 1773US10836824B2Antibodies directed against lymphocyte activation gene 3 (LAG-3)ANAPTYSBIO INC·Filed 2016·Granted Nov 17, 2020·1 cites·10 claims
- 1873US2025368739A1Antibodies Directed Against T Cell Immunoglobulin and Mucin Protein 3 (TIM-3)ANAPTYSBIO INC·Filed 2025·Application pending·0 cites
- 1972US12391761B2Antibodies directed against interleukin 36 receptor (IL-36R)ANAPTYSBIO INC·Filed 2021·Granted Aug 19, 2025·0 cites·18 claims
- 2069US2021163589A1Antibodies Directed Against Programmed Death-1(PD-1)ANAPTYSBIO INC·Filed 2020·Application pending·0 cites
- 2168US9260533B2Methods of generating libraries and uses thereofANAPTYSBIO INC·Filed 2014·Granted Feb 16, 2016·0 cites·34 claims
- 2267US9637556B2Methods of generating libraries and uses thereofANAPTYSBIO INC·Filed 2013·Granted May 2, 2017·0 cites·7 claims
- 2365US9951126B2Antibodies directed against nerve growth factor (NGF)ANAPTYSBIO INC·Filed 2014·Granted Apr 24, 2018·0 cites·2 claims
- 2464US2021095026A1Antibodies Directed Against Lymphocyte Activation Gene 3 (LAG-3)ANAPTYSBIO INC·Filed 2020·Application pending·0 cites
- 2562US2019256596A1Antibodies directed against lymphocyte activation gene 3 (lag-3)ANAPTYSBIO INC·Filed 2019·Application pending·0 cites
- 2660US2024084021A1Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativaANAPTYSBIO INC·Filed 2022·Application pending·0 cites
- 2759US2011183855A1Somatic hypermutation systemsANAPTYSBIO INC·Filed 2010·Application pending·0 cites
- 2857US8926978B2Antibodies directed against nerve growth factor (NGF)ANAPTYSBIO INC·Filed 2012·Granted Jan 6, 2015·0 cites·2 claims
- 2957US2019284280A1Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)ANAPTYSBIO INC·Filed 2017·Application pending·0 cites
- 3053US2025282872A1B and t lymphocyte attenuator (btla) modulators and method of using sameANAPTYSBIO INC·Filed 2023·Application pending·0 cites
- 3150US2023272092A1Anti-interleukin 36 receptor (il-36r) therapy for ichthyosisANAPTYSBIO INC·Filed 2021·Application pending·0 cites
- 3248US2024216506A1Antibody compositionANAPTYSBIO INC·Filed 2022·Application pending·0 cites
- 3345US2023391872A1B and t lymphocyte attenuator (btla) modulators and method of using sameANAPTYSBIO INC·Filed 2021·Application pending·0 cites
- 3445US2013102031A1Use of somatic hypermutation to create insertion and deletion mutations in vitroANAPTYSBIO INC·Filed 2012·Application pending·0 cites
- 3542US2014079691A1Thermostable antibody framework regionsANAPTYSBIO INC·Filed 2013·Application pending·0 cites
- 3641US2022235132A1Pd-1 agonist and method of using sameANAPTYSBIO INC·Filed 2020·Application pending·0 cites
- 3740US2020239562A1Anti-il-33 therapy for atopic dermatitisANAPTYSBIO INC·Filed 2018·Application pending·0 cites
- 3837US2013035472A1Method of producing transcripts using cryptic splice sitesANAPTYSBIO INC·Filed 2011·Application pending·0 cites
- 3935US2019016795A1Inhibition of allergic reaction using an il-33 inhibitorANAPTYSBIO INC·Filed 2017·Application pending·0 cites
- 4035US2017158762A1Antibodies directed against discoidin domain receptor family, member 1 (ddr1)ANAPTYSBIO INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ANAPTYSBIO INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →